Federal Biotechnology (Zhuhai Hengqin) Co., Ltd.

To study the efficacy and safety of degludec insulin liraglutide injection developed by United Biotechnology in patients with type 2 diabetes.

Main purpose: To investigate the pharmacokinetic characteristics of degludec and insulin aspart injection, and to compare the pharmacokinetic similarity of a single subcutaneous injection of degludec and insulin aspart (test preparation) with the original drug "Novogam®" (reference preparation) in healthy Chinese adult subjects. Secondary objectives: 1) To evaluate the safety of degludec and insulin aspart injection; 2) To preliminarily evaluate the immunogenicity of degludec and insulin aspart injection.

Primary objective: To evaluate the safety and tolerability (including local tolerance) of a single subcutaneous injection of UBT251 injection in healthy subjects. Secondary objective: To evaluate the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of a single subcutaneous injection of UBT251 injection in healthy subjects; To evaluate the immunogenicity characteristics of a single subcutaneous injection of UBT251 injection in healthy subjects.